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Management of Large Cell
Neuroendocrine Carcinoma
Virginia Corbett1, Susanne Arnold2, Lowell Anthony2 and Aman Chauhan2*
1 Department of Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States,
2 Division of Medical Oncology, Department of Internal Medicine, Markey Cancer Center, University of Kentucky,
Lexington, KY, United States
Background: Large cell neuroendocrine carcinoma (LCNEC) is a rare, aggressive cancer
with a dismal prognosis. The majority of cases occur in the lung and the gastrointestinal
tract; however, it can occur throughout the body. Recently advances in the understanding
of the molecular underpinnings of this disease have paved the way for additional novel
promising therapies. This review will discuss the current best evidence for management of
LCNEC and new directions in the classification and treatment of this rare disease.
Methods: We performed a PubMed search for “Large cell neuroendocrine carcinoma”
and “High grade neuroendocrine carcinoma.” All titles were screened for relevance to
the management of LCNEC. Papers were included based on relevance to the
management of LCNEC.
Results: Papers were included reviewing both pulmonary and extra pulmonary LCNEC.
We summarized the data driven best practices for the management of both early and
advanced stage LCNEC. We describe emerging therapies with promising potential.
Discussion: LCNEC are rare and aggressive neoplasms. In advanced disease, the
historical regimen of platinum based therapy in combination with etoposide or irinotecan
remains among the commonly used first line therapies, however for extra thoracic LCNEC
regimens like FOLFOX, FOLFOIRI and CAPTEM can also be used. Further effective and
safe treatment options are desperately needed. Recently, new advances including a new
understanding of the genetic subcategories of LCNEC and immunotherapy agents may
guide further treatments.
Keywords: LCNEC, large cell neuroendocrine carcinoma, high grade neuroendocrine carcinoma, clinical
management, future directions
INTRODUCTION
Large cell neuroendocrine carcinoma (LCNEC) is a rare subgroup of high grade neuroendocrine
cancer that can occur throughout the body (Figure 1). The most common primary site is the lung,
however, LCNEC also occurs in the gastrointestinal tract and in other locations including cervix,
uterus, kidney, bladder, prostate, pharynx, larynx and many other primary sites (Figure 2) (1–6).
LCNEC is an aggressive, fast growing neuroendocrine carcinoma, similar to small cell lung cancer
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(SCLC). The incidence of LCNEC is increasing worldwide. Most
LCNEC originates in the lungs and pulmonary LCNEC
represents 2 to 3.5% of all lung cancers (7). In studies using
SEER data, age adjusted incidence of pulmonary LCNEC is 0.3
per 100,000 with a rise by 0.011 people per 100,000 per year from
2004-2015 (8, 9). In addition to pulmonary LCNEC, there is
evidence that LCNEC of all sites are increasing. A Dutch registry
study of 47,800 patients with neuroendocrine tumors examined
LCNECs, revealing an increase in incidence of LCNEC of all sites
from 0.01 per 100,000 people to 1.8 per 100,000 people in 2010
(10). In this same population 5 year overall survival (OS) of
patients with LCNEC was 20% (10, 11). This manuscript is
intended to review current best evidence of management of this
rare and deadly disease as well as several promising new
directions for classification and treatment.
METHODS
The papers included in this review were primarily selected based
on expert opinion. However, for completeness a PubMed search
was performed for “Large cell neuroendocrine carcinoma” and
“High grade neuroendocrine carcinoma.” 3658 results were
obtained. All titles were screened for relevance to the
management of LCNEC. Of these 606 were further examined
with review of abstract and/or paper. Papers were included based
on relevance to the management of LCNEC. Data search was
completed on 12/31/2020. Only papers available in English were
included. Author VC completed the data review and paper
selection. Randomized control trial and large retrospective
reviews were prioritized, as were publications using the most
recent WHO neuroendocrine grading criteria for pulmonary or
digestive system neuroendocrine tumors. Given limited studies
available describing pure extra-pulmonary LCNEC, the majority
of extra-pulmonary studies presented included both SCNEC and
LCNEC. Breakdown of the number of LCNEC patients was
included when available. As the GI tract is the most common
site of extra-pulmonary disease, studies describing extra-
pulmonary LCNEC focused on GI primary tumors.
HISTOLOGIC CLASSIFICATION
As with all neuroendocrine tumors correct histopathological
classification of LCNEC is critical to diagnosis and treatment
planning. The classification of LCNEC has evolved rapidly in the
last 30 years. Pulmonary LCNEC was first named in 1991 when
Travis et al. proposed that LCNEC represented a distinct
category from SCLC (12). The 2004 WHO classification
included a category of non-small cell lung cancer called large
cell carcinoma which encompassed LCNEC and also several
other subtypes of large cell carcinomas including rhabdoid
phenotype, basaloid carcinoma, and lymphoepithelioma-like
carcinoma (13). During this period, there was debate over
FIGURE 1 | Spectrum of neuroendocrine neoplasms (NEN). This graphic demonstrates the spectrum of neuroendocrine tumors from low grade to high grade.
FIGURE 2 | Distribution of LCNEC based on site of origin. This graphic
shows the distribution of large cell neuroendocrine primary tumor locations.
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whether LCNEC should be classified as a non-small cell lung
cancer (NSCLC) or as a variant of SCLC (14). The 2015 WHO
classification of lung cancer (Table 1) created the current distinct
classification of pulmonary LCNEC from the more general
category of large cell carcinoma. In this classification
pulmonary high grade neuroendocrine carcinoma (HGNEC)
including LCNEC and SCLC have mitoses >10/2mm2 and the
presence of necrosis (13, 15). LCNEC can exist in combination
with other types of lung cancer including SCLC, adenocarcinoma,
and squamous cell carcinoma. Adenocarcinoma is the most
common combined component; in one retrospective study
median OS was not significantly different in pure LCNEC versus
combined adenocarcinoma and LCNEC (16). 2021 WHO
classification for lung neuroendocrine neoplasm will formally
introduce the combined category. This will be defined as
carcinoma with at least 25% of LCNEC or SCLC component
mixed with non-small cell carcinoma component. LCNEC
typically do not secrete vasoactive amines like some functional
low grade neuroendocrine tumors, however a variety of
paraneoplastic conditions have been described with pulmonary
LCNEC including ectopic ACTH production (17–20), cancer
associated retinopathy (21, 22), limbic encephalitis (23), Lambert
Eaton Syndrome (24, 25), and syndrome of inappropriate
antidiuretic hormone (SIADH) (26).
Gastrointestinal (GI) LCNEC has also undergone a recent
evolution in classification. The key distinction between well-
differentiated neuroendocrine tumors and high grade
neuroendocrine carcinoma was initially described in the 2000
WHO guidelines, which classified these tumors as poorly
differentiated. The 2010 guidelines changed to include distinct
groups including (i) grade 3 neuroendocrine carcinoma which
encompassed both LCNEC and small cell neuroendocrine
carcinoma (SCNEC), (ii) and all tumors with Ki-67 greater than 20
and mitotic index greater than 20 (27). The 2010 criteria also
described a new category of mixed adenoneuroendocrine
carcinoma (MANEC) with an adenocarcinoma and
neuroendocrine component. The 2010 criteria definition of G3 as
tumors with mitotic rate >20 mitosis per 2 mm2 and Ki-67 >20%
included both well differentiated neuroendocrine tumors with high
proliferation and poorly differentiated HGNEC such as LCNEC and
SCNEC. TheWHO2019GINET criteria included a new category of
well differentiated (G3) neuroendocrine tumors (Table 2). This
update reflects the recognition that well differentiated tumors can
be high grade but are distinct from SCNEC and LCNEC. TheWHO
2019 grading system also changed the terminology of mixed tumors





Pulmonary and extra-pulmonary LCNEC share many similar
clinical characteristics. Patients with pulmonary LCNEC were
more likely to be white males (9, 30). Patients with pulmonary
LCNEC are less likely to present with advanced stage disease as
compared to SCLC (31). Cough is the most common presenting
symptom of pulmonary LCNEC (32). Although pulmonary
LCNECs can occur throughout the lungs, they are most likely
to occur in the upper lung lobes (33). In large studies of GI
TABLE 1 | Adapted from 2015 WHO classification pulmonary neuroendocrine tumors (13, 15), With recent addition of “Combined morphology” from WHO 2021
classification.
Tumor Type Morphology Mitoses (Mitoses/
2 mm2)
Necrosis Other Characteristics:
Typical carcinoid Carcinoid <2 No
necrosis
Carcinoid morphology an <2 mitoses/2mm2,
lacking necrosis >0.5cm




Neuroendocrine >10 Necrosis Cytological features of NSCLC.
Small cell lung cancer Neuroendocrine >10 Necrosis Cytological features of SCLC
Combined with NSCC
component
Up to 25% LCNEC or 25% Small cell component in
combination with NSCC
NSCC, Non-small cell cancer; SCLC, Small cell lung cancer.
TABLE 2 | Adapted from 2019 WHO classification of tumors of the digestive system (28).
Terminology Differentiation Grade Mitotic rate (mitoses/2 mm2) Ki-67 (Percent)
NET, G1 Well differentiated Low <2 <3%
NET, G2 Well differentiated Intermediate 2-20 3-20%
NET, G3 Well differentiated High >20 20%
NEC, SCNEC Poorly differentiated High >20 >20%
NEC, LCNEC Poorly differentiated High >20 >20%
MiNEN Well or poorly differentiated Variable Variable Variable
NET, Neuroendocrine tumor; SCNEC, Small cell neuroendocrine carcinoma; LCNEC, Large cell neuroendocrine carcinoma; MiNEN, Mixed neuroendocrine-non neuroendocrine neoplasm.
Corbett et al. LCNEC Management
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HGNEC, most patients are also men, most patients are in their
60s, and most are white. The majority of patients also presented
with stage IV disease. In one large study the most common
primary site was the colon, followed by pancreas, and esophagus
(34). Other studies showed that the stomach and small intestine
were also frequent sites of HGNEC (35). Pulmonary LCNEC is
commonly associated with a smoking history (36, 37). In limited
data available, patients with a history of colorectal HGNEC are
slightly more likely to describe a history of smoking but the
contrast with nonsmokers is less pronounced than in pulmonary
disease. In addition common presenting symptoms include
abdominal pain, hematochezia, melena, and altered bowel
movements (38). Although data is limited in extra-pulmonary
LCNEC and OS is variable depending on primary site (39), in
large studies 5 year OS in pulmonary LCNEC was 16.7% (9) and
13.3% (40) in colorectal HGNEC. Brain metastasis are more
common in pulmonary LCNEC (12-19.2% at presentation in
large studies) (8, 41) versus 1.6% in GI HGNEC (31).
MOLECULAR CHARACTERISTICS
OF LCNEC
The most recent important innovations in LCNEC classification
have occurred in genomic analysis of these tumors. Prior reviews
have comprehensively examined the molecular characteristics of
pulmonary LCNEC (42). Briefly, George et al. performed
genomic and transcriptome analysis on pulmonary LCNEC,
comparing genomic alterations in LCNEC with adenocarcinomas
and squamous cell carcinoma. They found frequent mutations in
TP53, RB1, STK11 and KEAP1. They also describe less common
mutations in the RAS-pathway including KRAS, NRAS, Harvey rat
sarcoma viral oncogene homolog (HRAS). They identified two
molecularly defined subgroups. The first “type 1 LCNECs” with
STK11/KEAP1 alterations and a neuroendocrine profile similar to
SCLC with elevated ASCL1 and DLL3. George et al. also describe
“type II LCNEC” which has a genetic resemblance to SCLC with
TP53 and RB1 alterations, but with reduced activity of typical
neuroendocrine markers and higher NOTCH pathway activation
(43). PD-L1 (programmed death-ligand 1) and tumor mutational
burden (TMB) are known to be predictors of potential response to
immunotherapy (44) and have been evaluated in LCNEC. PD-L1
was evaluated in relation to the LCNEC subgroups revealing that
tumor PD-L1 ≥ 1% is expressed in 16% of metastatic LCNEC and
PD-L1 expression was not significantly different between the
molecular subgroups of LCNEC (45). Many other studies have
reported a similar percentage of PD-L1 expression in pulmonary
LCNEC (Table 3). Reported values for PD-L1 expression in tumor
cells (TC) range from 9.1% (53) to 74% (51). PD-L1 expression was
more common in stromal lymphocytes or local immune cells (IC)
and ranged from 37% (48) to 75% (47).
Further investigations into molecular subtypes of pulmonary
LCNEC will have important treatment implications. Rekhtman
et al. explored next generation sequencing in pulmonary LCNEC.
This study revealed three clusters, each with similar molecular make
up, including 40% of cases with a “SCLC- like” with TP53 and RB1
alterations, and 56% of cases described as “NSCLC- like” with
STK11, KRAS, KEAP1-NFE2L2 alterations which are more typical
of adenocarcinoma or squamous cell carcinoma. This study also
showed both of these groups had elevated TMB slightly above 10
mutations/Megabase (Mb). Interestingly, in 4% of patients they
identify a “carcinoid-like subset” with MEN1 alterations and low
mutational burden (55). Another group also examined mutational
burden in pulmonary HGNEC including 39 LCNEC and 63 SCLC
cases. They found that the number of non-synoumous mutations
was significantly increased in patients with IC infiltration and PD-
L1 expression on ICs but not correlated to PD-L1 expression on
TCs (52). Another study examined TMB in pulmonary HGNEC in
300 patients with LCNEC and 887 with SCLC. They found the
median TMB in patients with pulmonary LCNEC was 9.9
mutations/Mb, the same as in the SCLC group (56).
The overlap between LCNEC and atypical carcinoid tumors
was also explored in another study. One group used clustering
analysis to compare the genomic profiles of 116 pulmonary
carcinoids (including 35 atypical carcinoids), 75 LCNEC and
66 SCLC. Of note, 6 atypical carcinoids clustered with LCNEC
patients with a similar survival. The authors suggest that these
“supra carcinoids” may represent a group of atypical carcinoid
tumors that progress to LCNEC over time (57).
One study examined driver gene status in 94 LCNECs. In this
study EGFR mutants were detected from peripheral blood with an
amplification refractory mutation system (ARMS) and anaplastic
lymphoma kinase (ALK) rearrangement was detected by
immunohistochemistry. They found driver mutations including
epidermal growth factor receptor (EGFR) (8.3%), anaplastic
lymphoma kinase (ALK) (5.8%) (58). Given the limited number
of cases the percentage of patients with ALK-mutated LCNEC that
respond to tyrosine kinase inhibitor (TKI) treatment is not known.
Limited case reports exist of patients with pure and mixed LCNEC
who have ALK rearrangements, and a few patients experienced
benefit from treatment with ALK inhibitors (59, 60). In another
study primary tumor location in 125 case of pulmonary LCNEC
was examined. Most patients had peripheral tumors. Central
tumors were associated with smoking history. Genomic DNA
was used for polymerase chain reaction (PCR) amplification and
sequencing of EGFR. RB1 was detected on IHC of tumor sample.
Peripheral tumors had a higher incidence of EGFR expression.
RB1 protein was more frequently expressed in peripheral tumors.
In a multivariate analyses of tumor location, resection status, and
EGFR mutational status were associated with improved OS (61).
Additional case reports of EGFR mutations in LCNEC have been
described, along with response to gefintib (62). These findings
suggest a potential role for molecular profiling in LCNEC.
There is less information available about the molecular
underpinnings of gastrointestinal LCNEC. A retrospective analysis
of pancreatic neuroendocrine carcinoma included 49 patients with
SCNEC and 18 patients with LCNEC. Immunohistochemistry was
reviewed and pRb proteins were identified by monoclonal
antibodies. KRAS codon 12 mutations were evaluated using
fluorescence-based DNA analysis, and the PCR. Of the LCNEC
patients, 17 were evaluable for genetic analysis and 4 patients,
Corbett et al. LCNEC Management
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TABLE 3 | Key papers describing PD-L1 expression in pulmonary LCNEC.
Study Number of
patients















(TMA) from US Biomax
• 3/5 cases with positive
TCs had 1% or less tumor
staining
• 5/10 cases with positive
ICs expressed 2% or less
positive cells.







(kit and automat Dako,
Dako, Agilent, USA)
• Positive TC % of TCs with
membrane PD-L1 labeling
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• Positive ICs = the % of the
IC surface labeled, IC
negative = <1%; IC1 = 1–
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shorter for metastatic LCNEC patients

















>1% 17/76 (22%) 28/76 (37%) • Patients with both positive TC
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Autostainer Link 48 system
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pharmDx kit (DAKO,
Agilent, USA)
Tumor proportion score (TPS)
defined as % of tumor cells
with complete or partial
membranous staining at any
intensity. TPS ≥ 1% was
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16/98 (16%) N/A • CD8 expression also documented.
CD8 expression in tumor and stroma










Danvers, MA; diluted 1:50)
≥5% were categorized as
“PD‐L1 positive”
11/41 (27%) N/A • In combined assessment of 74 SCLC
and 41 LCNEC PD-L1 expression











≥1% was considered as PD-L1
positive
5/58 (9%) 25/58 (44%) • In combined assessment of 127
SCLC and 58 LCNEC samples, PD-
L1 positivity in IC but not TC was
associated with CD8+ infiltration,
increased tumor associated













(>1%) 33/72 (46%) • IC infiltration and PD-L1 expression
on IC was more strongly correlated in











Tumors with score ≥ 1 were
graded as PD-L1 positive
70/95 (74%) N/A • Patients with PD-L1 positive TC had









Inc., Danvers, MA, USA)
Semi quantitative H-score
method, score used by
multiplying the percentage of
tumor area by staining intensity.
Score of 1 was used as cutoff.
11/106
(10.4%)
N/A • PD-L1 status was also assessed in
SCLC and was 5.8% as compared to
10.4% in LCNEC.
PD-L1, Programmed death-ligand 1; SCNEC, Small cell neuroendocrine carcinoma; LCNEC, Large cell neuroendocrine carcinoma; N/A, not available.
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(23.5%), had retained RB and KRAS (wild type) and 14 (82.3%) had
RB loss and/or KRAS mutation. Of the 18 patients with LCNEC of
the pancreas the response rate to first line platinum-based therapy
was 40% compared to 65.2% in the 31 SCNEC patients. They
analyzed the combined pancreatic LCNEC and SCNEC cohort and
found that RB and KRASmutations were associated with improved
response to platinum-containing therapy (63).
Another study examined next generation sequencing and
pathology of 19 poorly differentiated pancreatic neuroendocrine
carcinomas with 10 LCNEC and 9 SCNEC. Immunohistochemical
labeling was done for proteins including pRb, p53, PAX8 among
others. Genomic DNA was extracted from and PCR amplification
was performed on genomic DNA or whole-genome amplification
for KRAS, TP53, CDKN2A/p16, and RB1. In this study 5 of 10
LCNEC patients expressed PDX1 (pancreatic duodenal homeobox
1), 5 of 10 LCNEC also expressed PAX, a transcription factor
expressed in well differentiated pancreatic neuroendocrine tumors.
Abnormal TP53 expression was found in 9 of the 10 LCNEC cases
and RB1 expression loss in 6 of 10 LCNEC patients. Of note,
overexpression of BCL-2 was observed in 9 of 9 of the SCNECs and
5 of the 10 LCNECs (64).
Although testing for microsatellite instability (MSI) is routinely
done for colorectal adenocarcinoma, few studies reported testing for
MSI in gastrointestinal neuroendocrine carcinoma. One study
reviewed 40 cases of gastrointestinal neuroendocrine carcinoma
including both SCNEC and LCNEC, with 10 cases of colorectal
neuroendocrine carcinoma (5 SCLC and 5 LCNEC).MSI cases were
detected using immunohistochemistry for the mismatch repair
(MMR) proteins MLH1, PMS2, MSH2, and MSH6. Of the 40
cases included, MSI was found in 3 cases, all were cecal
neuroendocrine carcinomas (65). Limited studies have evaluated
PD-L1 expression in GI HGNEC (Table 4). In one study of 33
patients with GI HGNEC 29% of patients had PD-L1 expression in
TCs. TMB was also measured with a range from 0.57 to 11.75
mutations/Mb, with a median TMB of 5.68 mutations/Mb (67). In
gastric NEC (4 LCNEC and 39 SCNEC) 48.8% of cases in the
combined cohort had TC expression of PD-L1 (68).
As previously described studies in pulmonary LCENC have
suggested that a possible subset of atypical carcinoid tumors
progress to LCNEC over time (57). A similar study was done in
gastroenteropancreatic tumors which evaluated a next
generation sequencing analysis of neuroendocrine neoplasms
with unsupervised cluster analysis which revealed 3 histology
independent clusters. Each cluster contained similar genetic
mutations shared by neuroendocrine tumors (NETs) and
HGNEC, including well differentiated NETs with high grade
components. The authors suggest that some NETs may progress
to secondary LCNEC over time (69). Although these theories are
still novel and require further exploration, they highlight the
many recent innovations in genetic analysis of these tumors.
DIAGNOSIS
Biopsy must be obtained to confirm diagnosis. Diagnosis is made
based on neuroendocrine morphology, mitotic count, presence of
necrosis, and proliferation rate as assessed by Ki-67. Confirmation
of neuroendocrine differentiation is needed using immuno
histochemical markers. Core biopsy samples are preferred as in
small tumor samples diagnosis can be difficult in fine needle aspirate
due to crushed tumor cells (15). It is to be noted that LCNEC are
often diagnosed postoperatively based on surgical specimen.
Limited fine needle aspirate tissue especially from lung lesion is
often not able to confirm the diagnosis. Despite the preference for
larger samples endobronchial ultrasound-guided transbronchial
needle aspiration has been shown to be effective in diagnosis of
LCNEC (70). For pulmonary and gastrointestinal primary sites
cross sectional imaging should be done for staging including CT of
the chest, abdomen, and pelvis with intravenous contrast. If a
gastrointestinal LCNEC primary is suspected, further imaging
with MRI of the abdomen and pelvis with contrast (Eovist
preferred) while non-contrast chest CT can be considered. MRI
of the brain should also be considered for staging at presentation in
pulmonary LCNEC. A small retrospective study of 37 patients with
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PD-L1, Programmed death-ligand 1; SCNEC, Small cell neuroendocrine carcinoma; LCNEC, Large cell neuroendocrine carcinoma; HGNEC, High grade neuroendocrine carcinoma; TMB,
Tumor mutational burden; Mb, Megabase; N/A, not available.
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LCNEC compared to 76 patients with SCLC, revealed 16.2% of
LCNEC patients presented with brain metastasis compared to
18.5% in SCLC patients (71). FDG- PET/CT is also
recommended at baseline for assessment of disease burden.
Somatostatin receptor scintigraphy with imaging such as Gallium-
68 DOTATATE PET/CT can be considered in select cases,
especially if the clinical course is following a relatively indolent
course, for potential screening for somatostatin receptor type 2
(SSTR-2) targeted clinical trials. One large retrospective study of
gastroenteropancreatic neuroendocrine neoplasms examined SSTR-
2 in 163 patients with high grade gastroenteropancreatic
neuroendocrine tumors or cancer of unknown primary. Of this
group 128 were patients with LCNEC, with 36 patients (22.1%)
strongly positive for SSTR-2 on immunohistochemical examination
(72). Another study examined SSTR-2 expression retrospectively in
218 pulmonary neuroendocrine tumors, including 60 cases of
LCNEC. In this study 20 (33%) of these patients were positive for
SSTR-2 on immunohistochemical examination (73).
Unlike well-differentiated neuroendocrine tumors, high grade
neuroendocrine carcinomas are rarely functional. Some institutions
use peripheral blood measurements of chromogranin A (CgA) and
neuron specific enolase (NSE) as these have been shown to be
elevated in some patients with high grade neuroendocrine
carcinoma including SCLC and some LCNEC patients (74). In
SCLC elevated NSE is a negative prognostic factor (75). NSE was
also examined in a retrospective cohort of poorly differentiated
gastroenteropancreatic neuroendocrine tumors, which included both
LCNEC and SCLC. In this combined cohort elevated NSE greater
than two times the upper limited of normal was associated with a
worse overall survival (76).
As described above emerging data suggests a potential role for
next generation sequencing in patients with LCNEC of all primary
sites. Although there is not yet robust data to suggest testing in all
patients, next generation sequencing should be considered.
TREATMENT
Stage I-III
Surgery should be considered first line treatment in all patients
with early stage pulmonary (I-III) LCNEC. Retrospective data
suggests that in pathologic limited stage disease, surgical resection,
most commonly lobectomy, was associated with a 5 year OS of
49.2% (77). In a large propensity-matched retrospective study
using SEER data in patients with pulmonary LCNEC, surgery was
associated with improved overall survival. This study examined
473 patients with pathologic stage IA pulmonary LCNEC and
compared outcomes with patients with lung adenocarcinoma and
squamous cell cancer. For LCNEC patients median OS was 66.0
months and 5 year OS rates 52.5% (33). In terms of the type of
surgery, for pathologic stage I and II pulmonary LCNEC,
lobectomy and pneumonectomy have been shown to have
improved survival (78). To better evaluate the optimal type of
surgery Lufti et al. retrospectively examined patients with
pathologic stage I LCNEC and compared 5 year OS in patients
who had a sub-lobar resection (wedge or segmentectomy) as
compared to patients who had lobectomy. They found sub-lobar
resection in early stage LCNEC was associated with a lower 5-year
OS rate compared to lobectomy on unadjusted and propensity
matched analyses (79).
A retrospective study of 139 patients with pulmonary LCNEC
was done, all patients underwent surgery (majority were
lobectomies) with curative intent. In this group 5 year OS was
53%, 5 year disease free survival was 39% (80). Although there is
less data available in extra pulmonary LCNEC, limited studies of
high grade gastroenteropancreatic neuroendocrine carcinoma
show improved survival in patients who undergo resection for
early clinical stage disease. One retrospective study reviewed 600
high grade high-grade gastroenteropancreatic neuroendocrine
tumors with 335 patient who presented with limited clinical stage
at diagnosis. Of these patients 89% underwent surgery and
median survival for patients undergoing surgery was 153
months vs. 71 months for those not undergoing surgery (81).
Another study reviewed outcomes in high grade pancreatic
neuroendocrine carcinoma patients undergoing surgery. This
group included 28 patients who underwent surgery and 14
patients who underwent resection of the primary tumor in
clinically early stage disease with curative intent. All patients
recurred, the median time to recurrence or metastasis in this
group was 7 months (range 2–14 months). Resection of the
primary tumor was an independent prognostic factor of
improved survival for patients after occurrence of metastatic
disease (82).
Three prospective clinical trials have evaluated adjuvant
treatments for pulmonary LCNEC (Table 5). They include a
one arm nonrandomized trial of adjuvant cisplatin and
etoposide, compared to a control of historical data from the
same institution. In this study 15 men received adjuvant cisplatin
and etoposide for 1 or 2 cycles after completing lobectomy with
lymph node dissection for LCNEC. This trial revealed a 5 year
OS of 88.9% as compare to historical control of 47.4% (83).
Another prospective phase II study evaluated 4 cycles of adjuvant
irinotecan and cisplatin after complete resection of pulmonary
LCNEC and SCLC tumors (95% of patients received a
lobectomy). In the 23 patients with LCNEC, OS at 3 years was
86% (84). Recently the results were published of a phase III
randomized control trial comparing adjuvant cisplatin and
irinotecan versus etoposide plus cisplatin in patients with
pathologic stage I-IIIA resected HGNEC. The initial primary
endpoint of this study was overall survival; however, the primary
endpoint was changed to relapsed free survival (RFS) as there
were too few events for analysis of OS after accrual was
completed. In total 221 patients were enrolled, of these 74 had
pure LCNEC (38 were treated with etoposide and cisplatin and
36 with irinotecan and cisplatin). There was no significant
difference in 2 year RFS between the treatment arms, etoposide
and cisplatin 65.4% vs irinotecan and cisplatin 69%, P = 0.619.
Median RFS was not reached. In a subgroup analysis there was
no significance difference among patients with LCNEC or
combined LCNEC (85, 93).
Several retrospective reviews exist of adjuvant therapy for
pulmonary LCNEC. Most studies also suggest benefit of adjuvant
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TABLE 5 | Key Papers Describing Adjuvant Therapy in Pulmonary LCNEC.











15 LCNEC Etoposide / Cisplatin • 2 year OS 88.9% in the adjuvant chemotherapy group vs 65.2% in the
control group.








HGNEC (both SCLC and
LCNEC)
40 (23 LCNEC and 17
SCLC)





open-label, phase III study
Stage I-IIIA completely
resected pulmonary
HGNEC (both SCLC and
LCNEC)
221 (74 LCNEC and 78
SCLC, 39 combined SCLC
and 20 combined LCNEC)
Etoposide/Cisplatin (111
patients) vs Irinotecan /
Cisplatin (110 patients)
• No significance difference in 3 year RFS between treatments arms
(Etoposide/Cisplatin arm 65.4% and Irinotecan/Cisplatin arm was 69%).




Retrospective review Pure pulmonary LCNEC
who underwent surgical
resection
83 Variable • 5 year OS 27.6%, stage I, 33%, stage II, 23% and stage III, 8%.
• Of 13 patients who received adjuvant chemotherapy patients with
SCLC based treatment (cisplatin/etoposide) had improved overall
survival compared to other NSCLC based treatments.
Veronesi
et al. (87)
Retrospective review Consecutive patients with
surgical resection of
pulmonary LCNEC
144 Variable • 5 year OS was 42.5%; for stage I, 52%, stage II, 59%, and stage III,
20%.
• Patients with stage I disease who received chemotherapy tended to
survive longer than those who received no chemotherapy (p = 0.077).
Iyoda
et al. (88)
Retrospective review LCNEC patients with
surgical resection of
primary tumors
72 Variable • 5 year DFS was 42.7%, 5 year OS for patients with recurrent tumors
was 12.5%.
• Receiving platinum based adjuvant chemotherapy was associated with




Retrospective Review Resected LCNEC 100 Variable • Median OS was 3.4 years.
• 20 of 71 patients with stage I-II resected disease received platinum
based chemotherapy. The 5 year OS was 37% for patients who did not




Retrospective Review Resected LCNEC or
mixed LCNEC
45 Variable • 2 year OS was 89.2% and 5 year OS was 69.4%.
• 5 year survival rates of patients who underwent perioperative adjuvant
chemotherapy was significantly higher (87.5%) than those who
underwent surgery alone (58.8%).
Kujtan
et al. (91)
Retrospective review Stage I LCNEC 1232 (957 surgical resection
alone, 275 both surgery and
systemic chemotherapy)
Variable • OS in univariate 30 day analysis was significantly improved in patients
who received chemotherapy across the whole cohort.
• 5 year OS was significantly improved in patients who received both
surgery and systemic chemotherapy as compared to those who
received chemotherapy alone (64.5% versus 48.4%).
Raman
et al. (92)
Retrospective review Stage I LCNEC 2642 Variable • 5 year OS was 53%, univariable analysis showed a significant increase
in OS with adjuvant therapy for stage I LCNEC compared with no
adjuvant therapy.
• In subgroup analysis of stage IA patients (n=2055) there was no
significant survival benefit for adjuvant therapy, however significant
survival benefit was present in stage IB patients (N= 587).
Shen et al.
(58)
Retrospective review Surgically resected
LCNEC
94 Variable • Of 75 patients who received adjuvant chemotherapy patients who
received platinum /etoposide base regimens had improved DFS as
compared to NSCLC regiments.
































chemotherapy after resection for early stage disease. In a large
retrospective study of 1232 resected pathologic stage I
pulmonary LCNEC 5 year OS was significantly improved in
patients who received both surgery and systemic chemotherapy
as compared to those who received chemotherapy alone (64.5%
versus 48.4%) (91). Saji et al., retrospectively reviewed 45 patients
with pulmonary LCNEC who underwent surgical resection and
received perioperative chemotherapy (7 with induction and 16
with adjuvant therapy). They found significantly improved 5
year OS in patients who received perioperative chemotherapy
(87.5%) compared to those who received surgery alone (58.8%)
(90). A large retrospective study of 1232 patients who underwent
surgical resection for pathologic stage 1 LCNEC included 957
patients with surgery resection alone and 275 who received
surgery and chemotherapy. The majority of patients in this
study had stage IA disease. 5 year OS was significantly
improved in patients who received chemotherapy (64.5%) as
compared to patients who received surgery alone (48.4%) (91). In
another large retrospective study subgroup analysis was done for
stage IA versus stage IB cases. They found in subgroup analysis of
stage IA patients (N=2055) there was no significant survival
benefit for adjuvant therapy, however significant survival benefit
was present in stage IB patients (N= 587) (92).
In summary most studies suggest that adjuvant chemotherapy
improves OS in patients with localized LCNEC. The evidence for
this is best in stage IA disease. Platinum based chemotherapy with
either irinotecan or etoposide is commonly used. The best
evidence for these two agents is the prospective, randomized
phase III trial from Kenmotsu et al. (85) which found no
significant difference in 3 year RFS between these two regimens.
In extra pulmonary LCNEC no prospective studies were
identified evaluating adjuvant chemotherapy. Several
retrospective studies have been done (Table 6), most include
HGNEC with cohorts combining patients with SCNEC and
LCNEC. In a review of 119 patients with high grade pancreatic
neuroendocrine carcinoma patients who underwent surgical
resection there was improved 3 year OS compared to those
without resection. The patients who underwent resection in this
study also underwent adjuvant chemotherapy, the majority with
cisplatin and etoposide or carboplatin and etoposide. These data
suggests that patients who could tolerate more than four courses
of adjuvant chemotherapy had improved outcomes (82). In
another retrospective study of 39 gastric high grade
neuroendocrine carcinomas, including 39 SCNECs and 4
LCNECs, all patients had surgical resection and most received
postoperative chemotherapy. The largest group (14) of patients
received adjuvant fluoropyrimidine-based regimens, including 5-
fluorouracil, leucovorin, oxaliplatin combination regimen
(FOLFOX) and capecitabine plus oxaliplatin. For those that
received postoperative chemotherapy the median overall
TABLE 6 | Adjuvant therapy extra-pulmonary LCNEC (most studies report outcomes for combined SCNEC and LCNEC patient populations).
Study Study
Design






HGNEC of the colon and
rectum
126 HGNEC Variable • 3 year OS was 8.7%, median survival 13.2 months
• 5 year OS 5% in metastatic disease and 18% in non-
metastatic disease










119 patients Variable • 3 year survival rate after primary surgery and metastatic
disease was 69%.
• Patients who underwent combined surgery and
chemotherapy had significantly improved survival as












Variable • 3 year OS was 44.51%, 5 year OS was 35.05%.
• 34 patients had adjuvant chemotherapy with median OS 44
months as compared to 14 months in 5 patients who did







carcinoma of the colon
and rectum.
1208 patients (653
SCNEC and 556 LCNEC)
Variable • Median OS 9.0 months, 3 year OS was 17.8% and 5 year
OS was 13.3%.
• For localized disease 5 year OS was 15.9% in patients who
received only chemotherapy, 31.7% only surgery, and 37%










1861 patients Variable • 519 patients underwent surgery, 224 patients received
post-operative chemotherapy which was associated with












759 patients Variable • 213 patients received post-operative chemotherapy after
curative resection. For these patients post-operative
chemotherapy was not associated with improved overall
survival.
• 5 year OS in the chemotherapy group was 39% compared
to 45% in patients that did not receive post-operative
treatment
HGNEC, High grade neuroendocrine carcinoma; OS, overall survival; LCNEC, Large cell neuroendocrine carcinoma; SCNEC, Small cell neuroendocrine carcinoma.
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survival was 44 months compared to 15 months in 5 patients
who did not receive chemotherapy post-operatively (96). In a
series of 126 patients with colon, rectal, and anal high grade
neuroendocrine carcinoma, surgical resection and adjuvant
chemotherapy in localized disease did not improve overall
survivial (94). A recent large study of 759 patients in the
National Cancer Database examined outcomes with post-
operative chemotherapy after curative resection. In this study
37.7% of patients had primary tumors in the pancreas, 25.7% had
gastric, and 36.6% of patients had tumors that originated in the
small intestine. This study used inverse probability of treatment
weighting (IPTW) to reduce selection bias and compared post-
operative chemotherapy with observation. In this study, 28.1% of
patients received postoperative chemotherapy after curative
resection, and IPTW showed no OS benefit in the overall
group. In a subgroup analysis, paradoxically there was
improved survival benefit in the observational arm of the small
intestinal group as compared the postoperative chemotherapy
group (35). Taken in total the data for post-operative
chemotherapy after surgery is mixed. One explanation for
mixed results is that the very aggressive nature of this disease
leads to recurrence of disease despite surgical resection and
adjuvant chemotherapy. Further trials, especially prospective,
randomized control trials are needed to clarify the true benefit of
adjuvant chemotherapy in resected GI HGNEC.
Radiation
In several retrospective studies post-operative radiation after
resection for early stage pulmonary LCNEC does not improve
survival. In addition when compared with surgery followed by
radiation, patients who received surgery combined with
chemotherapy had improved survival (97, 98).
In patients with early stage pulmonary LCNEC that are not
surgical candidates, radiation may be considered as primary
therapy. For patients with stage III disease (not surgical
candidates) radiotherapy was associated with a significant
increase in overall survival (97). One retrospective study of
SEER data used propensity-matched analysis to compare
stereotact ic ablat ive body radiotherapy (SABR) to
conventionally fractionated radiation therapy in patients with
early stage pulmonary LCNEC that were not surgical candidates.
In this study SABR was associated with improved OS (99).
There is limited data on the role of prophylactic cranial
radiation (PCI) in early stage LCNEC. In retrospective studies
PCI is used significantly less in LCNEC as compared to SCLC,
and in one study, only 4% of patients received PCI (100).
Cumulative risk of brain metastases in LCNEC increases over
time in patients with advanced disease treated with first line
carboplatin and etoposide. In patients with stage III or IV disease
at diagnosis, the risk of brain recurrence reaches 58% to 48% at
18 months after diagnosis (71). Another large study found that in
23 patients with metastatic LCNEC without brain metastasis, 6
(23%) went on to develop brain metastases during clinical follow
up (41). Another study of pulmonary LCNEC using SEER data
noted a rate of brain metastases of 19.2% as compared to 16.7%
in SCLC (8). A retrospective study of 72 patients with advanced
or metastatic LCNEC and SCLC included 21 patients treated
with PCI (17 SCLC and 4 LCNEC). In this small group of
LCNEC patients, PCI was associated with higher progression free
survival (PFS) and median OS (101). In another retrospective
study, 70 patients with pulmonary LCNEC were reviewed.
Almost all (94%) of patients underwent surgery as the first line
treatment. In this study 20% patients received adjuvant
chemotherapy and/or radiotherapy and prophylactic whole
brain radiotherapy (WBRT). They found that in patients who
did not receive PCI at median follow up of 23.4 months, 25%
developed brain metastasis. At 5 years after diagnosis overall
survival was 43% (100). Further trials are needed to clarify the
role of PCI in this population. If patients with pulmonary
LCNEC are found to have brain metastasis, stereotactic
radiosurgery (SRS) is associated with improved survival (102).
There is limited data available on the role of tumor directed
radiation and PCI in extra pulmonary LCNEC however in
retrospective series fewer brain metastasis are seen in extra
pulmonary as compared to pulmonary LCNEC. In one
retrospective review of high grade neuroendocrine carcinoma
of the colon and rectum (combining both LCNEC and SCNEC)
only 2 of 126 patients presented with brain metastasis at
diagnosis (94). In another large retrospective study of high
grade extra pulmonary neuroendocrine carcinoma (including
both LCNEC and SCNEC) only 1.6% of patients had brain
metastases at presentation (34). Given the low risk of brain
metastases PCI is not routinely done in this patient population.
Stage IV
In patients who present with advanced pulmonary LCNEC there
have been 2 prospective trials examining first line systemic
treatment and several retrospective studies (Table 7).
Niho et al., performed a single arm phase II study of
irinotecan and cisplatin as first line therapy in advanced
pulmonary LCNEC. Of 44 patients enrolled, response rate in
the intention to treat group was 54.5%. Median PFS was 5.9
months and median OS was 15.1 months. Upon central
pathology review, 20 of these patients had pure LCENC. The
response rate in the pure LCNEC group was 46.7%. Median
overall survival was 12.6 months in the pure LCNEC group (14).
In a second trial Le Treut et al. performed a prospective, single
arm phase II study of advanced stage LCNEC treated with
cisplatin and etoposide. This study enrolled 42 patients with
advanced LCNEC of the lung. Upon central pathologist review,
29 of the 40 patients with tissue available for review were pure
LCNEC. The objective response was 38%, with a 64% disease
control rate. Median PFS in the intention to treat population was
5.3 months and the median overall survival was 7.7 months
(103). Given the small number of patients included in each of
these trials and the fact that the two regimens have never been
directly compared in randomized control trials, it is hard to draw
any specific conclusions about irinotecan and cisplatin versus
cisplatin and etoposide in this patient population.
Retrospective studies have also sought to explore these
questions. One retrospective from the Netherlands examined
207 patients with LCNEC who were treated with 3 different
regimens, a platinum (carboplatin, cisplatin) plus either
gemcitabine, docetaxel, paclitaxel or vinorelbine (called by the
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authors NSCLC-t), pemetrexed (called NSCLC-pt), or etoposide
(called SCLC-t). They found improved median OS in the
NSCLC-t group of 8.4 months, compared to 5.9 months in the
NSCLC-pt group and 6.7 months in the SCLC-t group.
Specifically, the biggest advantage to the NSCLC-t treatment
program was in treatment of a platinum combined with
gemcitabine (104). The same group examined 148 patients
with LCNEC who had next generation sequencing performed
and correlated molecular markers with overall survival and PFS.
They also stratified response for NSCLC chemotherapy including
platinum and gemcitabine or taxanes versus platinum and
etoposide combinations. They concluded that patients with
LCNEC that carry a wild type RB1 gene have improved
outcomes with platinum and gemcitabine or taxanes (NSCLC
regimens) versus platinum and episode based treatment (105).
This study was limited by its retrospective nature and small
patient population. Other groups have sought to stratify LCNEC
by novel genomic subtypes described above (43). In a
retrospective study of 63 patients with advanced LCNEC
patients were stratified by tumor mutation into SCLC-like and
NSCLC- like LCNEC based on genomic features from tumor
DNA or circulating free DNA. They found treatment with
platinum and etoposide was associated with superior response
and survival in SCLC-like LCNEC. However, treatment with
gemcitabine, taxane and platinum was not associated with
improved survival in NSCLC-like LCNEC (106). Additional
studies are needed to better evaluate how molecular subtypes
of LCNEC influence outcomes.
No prospective clinical trials for second and third line
treatments in metastatic pulmonary LCNEC were identified
(Table 8). Two retrospective studies examined amrubicin
monotherapy as a second line treatment for pulmonary
LCNEC. The first study included 18 patients with LCNEC or
“high-grade non-small-cell neuroendocrine carcinoma” all of
TABLE 7 | Key Papers Describing First Line Therapy in Metastatic Pulmonary LCNEC.
Study Study Design Patient
population














Etoposide/Cisplatin • For whole cohort median OS 7.7 months, ORR
38%, 64% DCR, at 1 year OS was 26.8%.














Irinotecan/ Cisplatin • ORR in pure LCNEC was 46.7%, median OS 12.6
months.










207 patients 3 groups of chemotherapy
regimens reviewed:
• Median OS 7.3 months.
• NSCLC-t group with median OS of 8.5 months vs
median OS of 5.9 months in NSCLC-t group and























3 regimens compared: • LCNEC with wild type RB1 gene showed
significantly longer OS when treated with platinum
with gemcitabine / taxane (9.6 months) as
compared to platinum / etoposide (5.8 months).
• Platinum with gemcitabine
/ taxane


















3 regimens compared: • ORR from all chemotherapy regimens was 46.7% in
SCLC- like LCNEC as compared to 25.6% in
NSCLC- like LCNEC.
• In SCLC-like LCNEC RR (75%) to platinum/
etoposide was higher than platinum/ pemetrexed
(0%).
• In NSCLC-like LCNEC there was no difference in
RR between the three chemotherapy regimens,
however platinum/etoposide regimens were
associated with longer PFS (5.2 months) than
platinum/gemcitabine/taxane (2.5 months).
• Platinum with gemcitabine
/ taxane
• Platinum and etoposide
• Platinum/ pemetrexed
RFA, recurrence free survival; OS, overall survival; LCNEC, Large cell neuroendocrine carcinoma; SCLC, Small cell Lung Cancer; DFS, Disease free survival; NSCLC, Non-small cell lung
cancer; DCR, Disease control rate; ORR, Overall response rate.
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whom had received platinum based first line therapy. The overall
response rate to single agent amrubicin was 11.1%. with median
PFS of 4.0 and median OS of 9.1 months (114). Another
retrospective study also examined amrubicin in advanced
pulmonary LCNEC after progression on platinum-based
chemotherapy. This study include 18 patients; objective
response rate (ORR) was 28%, median PFS was 3.1 months
and OS was 5.1 months (115).
In advanced extra-pulmonary LCNEC two prospective
studies have evaluated treatment in GI HGNEC (Table 9). Li
et al. completed a prospective, single arm phase II study of
irinotecan and cisplatin followed by octreotide LAR
maintenance. This study included 8 LCNEC patients. In total
ORR was 45% and median OS was 12.8 months (107). A recent
two-stage phase II study was done to evaluate the efficacy and
safety of a first line capecitabine, oxaliplatin, irinotecan, and
bevacizumab (CAPOXIRI-BEV) combination followed by
pazopanib plus capecitabine maintenance therapy in patients
with advanced GI HGNEC. In the 22 patients enrolled, ORR was
47.7% and overall disease control rate was 78.9%. Median PFS
was 13 months and median OS was 29 months. Subcategories of
LCNEC versus SCLC were not reported (108). Currently a
randomized phase II trial (the SENECA trial) of folinic acid, 5-
fluorouracil and irinotecan (FOLFIRI) or capecitabine plus
temozolomide (CAPTEM) as 2nd line therapy in advanced
extra-pulmonary HGNEC is being planned to better
understand this topic (117).
There are several retrospective studies examining efficacy of
first line chemotherapy in metastatic GI HGNEC. The efficacy of
platinum-based chemotherapy was retrospectively reviewed in
20 patients with GI HGNEC. Of the 20 patients in this review, 7
had LCNEC, and all received both FDG PET/CT scan and
Gallium 68 DOTATATE PET/CT scans. Of included patients,
80% had positive FDG PET/CT scans and 35% had positive
Gallium 68 DOTATATE PET/CT scans. In this study 75% of
patients received cisplatin and etoposide as first line treatment
TABLE 8 | First Line Therapy in Metastatic Extra-Pulmonary LCNEC (most studies report outcomes for cohorts with combined SCNEC and LCNEC).
Study Study
Design
Patient population Total Patients Treatment Outcomes Other







40 (20 SCNEC, 8
LCNEC, 7 MANEC, 5
NET w/ elevated Ki-67)
• Irinotecan/Cisplatin followed by octreotide
LAR maintenance
• 32 patients evaluable for
tumor response, ORR
45%, DCR 70%








carcinoma of the colon
or small bowel
22 patients • First line capecitabine, irinotecan,
oxaliplatin plus bevacizumab, for 6
cycles, if disease responding or stable,
patients received maintenance therapy
with pazopanib and capecitabine.
• 19 patients evaluable, ORR
47.4% (3 CR, 6 PR)
• Median PFS 13 months,











• Etoposide/Cisplatin was given in 29/41
of poorly differentiated patients
• Median OS for poorly
differentiated tumors was
2.3 months











41 patients • 18 patients received Etoposide/Cisplatin
• 22 patients received Irinotecan/Cisplatin
• Median OS was 9.2 months
• Patients who received
Etoposide/Cisplatin had
median OS of 7.3 months















• Irinotecan combined with 5-fluorouracil
and leucovorin
• PR in 7 patients (ORR 63.6%)















• Variable, most common
regimens irinotecan/cisplatin,
etoposide/cisplatin, and 5-FU based
regimens
• Median OS was 11.5 months
• ORR in irinotecan/cisplatin
50%, median OS 13
months, etoposide/cisplatin












• Most common regimen etoposide/cisplatin • Median OS was 13.5 months
• Patients with BMI ≥25 kg/
m2 had a poor prognosis
as did patients with Ki-67
>55%
NET, Neuroendocrine tumor; OS, overall survival; LCNEC, Large cell neuroendocrine carcinoma; SCNEC, Small cell neuroendocrine carcinoma; Long-acting release, LAR; MANEC, mixed
adenoneuroendocrine carcinoma; BMI, Body mass index; ORR, overall response rate.
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and 25% received carboplatin and etoposide. The ORR was 68%
and median OS was 13.5 months. Interestingly, 2 patients
received peptide receptor radionuclide therapy (PRRT) as
second line treatment (113). A review of the national cancer
database of patients with HGNECs of the colon and rectum was
performed. 1208 cases were identified, with 46.7% of patients
presenting with metastatic disease. By multivariable analysis,
resection, chemotherapy, and rectal primary site were
associated with better OS. Median OS in this study was 9.0
months (40).
There is limited retrospective literature for second line
treatment in advanced GI HGNEC (Table 10). A systematic
review and meta-analysis by McNamara et al. reviewed second
line chemotherapy in advanced extra pulmonary poorly
differentiated neuroendocrine carcinoma including both SCLC
and LCNEC. This review identified 19 studies with 4 prospective
studies (2 of which do not yet have available results) and 15
retrospective studies with 582 patients. When all studies were
taken together median response rate was 18%. The ORR was 0%
for single agent first line therapies everolimus, temozolomide, and
topotecan. The ORR was 50% for amrubicin. In the whole cohort
median PFS was 2.5 months, median OS was 7.64 months (121).
Amrubicin was also retrospectively studied in another study as a
monotherapy for patients with platinum refractory disease. In this
study, 10 patients with progression on platinum based therapy for
metastatic GI HGNEC were included who received second line
amrubicin monotherapy. In this very small study 2 patients had a
partial response for an ORR of 20% (118).
One study retrospectively examined 5-fluorouracil and
oxaliplatin (FOLFOX) as second line treatment for high grade
neuroendocrine carcinoma. The study included 20 patients, 12
LCNEC, 7 SCNEC and 1 unknown primary; 12 of the 20 patients
had tumors of gastroenteropancreatic origin. In this study, 12
patients received FOLFOX as second line treatment and 8 as
third line. Median PFS was 3.5 months, median OS was 9.9
months, ORR was 29% (119). In GI HGNEC after progression on
platinum with etoposide or irinotecan, promising other agents
include 5-fluorouracil based regimens and amrubicin. There will
likely also be a role for immunotherapy in this population
moving forward, however additional studies are needed.
FUTURE DIRECTIONS
Although atezolizumab plus carboplatin and etoposide has been
established as the first line therapy in SCLC (122), the role of
immunotherapy has not been clearly established in LCNEC.
Most of the available data for the use of immunotherapy
agents in this population are from small retrospective case
series and case reports. Levra et al. reported an impressive
ORR of 60% in a case series of 10 patients with advanced
pulmonary LCNEC treated with single agent nivolumab or
pembrolizumb as a second line therapy. In this study median
PFS was 57 weeks (123). Other case reports have shown response
to nivolumab in patients with pulmonary LCNEC (124, 125). A
recent larger retrospective study reviewed 37 consecutive
patients with advanced pulmonary LCNEC. The patients were
divided into two groups N=23 patients treated with immunotherapy
and N=14 patients not treated with immunotherapy. In the group
treated with immunotherapy ORR was 33% and median PFS 4.2
months, median OS with immunotherapy was 11.8 months. These
outcomes were very similar to response to immunotherapy in
NSCLC (126). The Dual Anti-CTLA-4 and Anti-PD-1 Blockade in
Rare Tumors (DART) trial is a prospective, open-label, multicenter
phase II clinical trial of ipilimumab plus nivolumab across multiple
rare tumor cohorts. Patients were eligible if they had advanced non-
pancreatic neuroendocrine tumors with progression following at
least one line of standard systemic therapy. The neuroendocrine
cohort included 18 patients with HGNEC with gastrointestinal or
lung primaries. The breakdown of histologic subgroups, including
the specific number of patients with LCNEC was not reported.
For the group of all HGNEC patients ORR was 44% (127). Although
these studies series do suggest potential responses to immunotherapy
in LCNEC, larger studies are needed to both determine benefit of
immunotherapy as a monotherapy or in combination with
chemotherapy and to establish which patients benefit most from
immunotherapy treatment.
Another important area for study is biomarkers for response to
immunotherapy in LCNEC. As reviewed above, PD-L1 is an
important marker of response to immunotherapy in other cancer
types, the role in LCNEC is not yet defined. A recent retrospective
study reviewed 13 patients with pulmonary LCNEC treated with
TABLE 9 | Key Papers Describing 2nd/3rd Line treatments in Metastatic Pulmonary LCNEC.
Study Study
Design






Advanced LCNEC who received 1 (N=13) or 2 (N=5)
prior chemotherapy regimens, most received
platinum based therapy
18 patients 2nd or 3rd line
amrubicin
monotherapy
• 17 patients were evaluable,







LCNEC or high-grade neuroendocrine carcinoma
probably LCNEC, who underwent chemotherapy as
initial therapy
25 patients (12 patients
received 2nd line
chemotherapy
Variable • ORR to 2nd line therapy was
17%







neuroendocrine carcinoma or LCNEC, received first
line platinum based therapy
18 patients 2nd line
amrubicin
monotherapy
• ORR 11.1%, DCR 61.1%
• Median OS was 9.1 months
• Irinotecan monotherapy was
the most frequently used 3rd
line treatment
OS, overall survival; LCNEC, Large cell neuroendocrine carcinoma; SCNEC, Small cell neuroendocrine carcinoma; ORR, overall response rate; DCR, Disease control rate.
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either pembrolizuamb or nivolumab. In this study the ORR for anti-
PD-1 therapy was 39% and OS was 13.7 months. Perhaps most
interestingly among the 13 patients treated with immunotherapy 10
patients had PD-L1 negative tumors. The ORR among patients with
negative PD-L1 expression was 40%. High density of CD8 positive
tumor infiltrating lymphocytes (TILs) (≥38/mm2) was associated
with improved ORR. Response to immunotherapy was associated
with TP53mutation co-occurring with either PIK3CA or RB1 (128).
Further larger clinical trials are needed to evaluate whether PD-L1
status will be a useful marker for LCNEC response to biotherapy or
if molecular characteristics of these tumors can help guide treatment
to anti-PD-1 therapies. Circulating tumor cells (CTCs) and cell free
DNA (cfDNA) are used as liquid biopsy biomarkers in solid tumors
to monitor and assess response in recurrent or metastatic disease
and may have a role in identifying patients who could respond to
immunotherapy in LCNEC (129). One recent study evaluated blood
T cell repertoire alterations in stage IV pulmonary LCNEC patients
enrolled in a trial of carboplatin and paclitaxel. Patients with
pulmonary LCNEC had significant T-cell repertoire alterations (p
< 0.001) compared to age-matched smokers. Increased T cell
repertoire alterations were associated with better treatment
response and longer survival (130). Assessment of T cells in the
peripheral blood may also play a future role in prognostication and
treatment selection of LCNEC patients.
As stated above median TMB in pulmonary LCNEC has been
reported to be 9.9 mutations/Mb (56) and 5.68 mutations/Mb
(67) in GI HGNEC. Use of TMB as marker of response to
combined checkpoint inhibition was evaluated in SCLC in the
CheckMate 032 trial. This randomized, multicenter, open-label,
phase 1/2 trial of nivolumab ± ipilimumab evaluated nivolumab
monotherapy and nivolumab plus ipilimumab in advanced
SCLC after progression on prior therapy. Although not
statistically significant the results suggested a potential survival
benefit from nivolumab plus ipilimumab versus nivolumab
monotherapy for patients with a high TMB (131). Further
studies are needed to better determine prevalence and clinical
utility of elevated TMB in LCNEC.
The KEYNOTE-158 study is perhaps most notable for
evaluating response to pembrolizumab in patients with elevated
tumor mutation burden (TMB) which led to the FDA approval of
pembrolizumab for this indication. In this study elevated TMB
was defined as least 10 mutations per megabase. Patients with
elevated TMB above this cutoff had improved response to
pembrolizumab monotherapy (132). It is also important to note
that a definition of TMB high as 10 mutations per megabase may
not be the most meaningful measure in all tumor types. The TMB
cutoffs that is associated with improved overall survival with
immunotherapy varies between cancer subtypes. One study
evaluated cut off of TMB based on the top 20% of normalized
mutation burden for each cancer type. For example in renal cell
carcinoma cutoff was found to be 5.9 while in colorectal cancer
the cutoff was 52.2 (133). The cutoff for elevated TMBwith benefit
with immunotherapy in LCNEC is not known.
A retrospective cohort study of 2589 patients examined rare
solid tumors including neuroendocrine tumors for elevated TMB
(using the same cutoff of KEYNOTE-158 of 10 mutations per
Mb). They reviewed the same rare tumor types as in KEYNOTE-
158 and found that prevalence of high TMB was highest in SCLC
in 122 of 305 patients (40%) and in NETs in 48 of 164 tumors
(29.3%) (134). They do not provide breakdown of the NET
patients by WHO grading criteria, however a note does mention
that of 164 pts with NETs 90 had “lung large cell NET” and half
of these patients had elevated TMB. One might speculate that a
portion of these patients in fact had LCNEC rather than
carcinoid or atypical carcinoid tumors.
Recently several promising future therapy directions have
been reviewed in SCLC including Poly [ADP-ribose] polymerase
(PARP) inhibitors in combination with chemotherapy and
targeting of histone-lysine N-methyltransferase EZH2 (135).
PARP inhibitors may also have a role in LCNEC as LCNEC
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has been found to have elevated PARP1 in review of IHC of
LCNECs. However, strong PARP1 intensity was more frequent
in SCLC, in 87.5% of samples versus in 67.6% of LCNEC samples
(136). Similarly EZH2 expression is also elevated in LCNEC and
agents targeting EZH2 may be useful in LCNEC (137).
Another promising target for future immunotherapy research
is delta like protein 3 (DLL3) a Notch family receptor involved in
the achaete scute complex-like 1 (ASCL1) pathway. In murine
models, overexpression of DLL3 was associated with cell
proliferation, tumor growth and reduced apoptosis (138). A
retrospective study of 94 patients with metastatic pulmonary
LCNEC evaluated DLL3 expression. DLL3 expression was
considered positive if ≥ 1% of tumor cells showed cytoplasmic/
membranous or dot-like immunostaining. They found positive
DLL3 in 70/93 (74%) samples (139). DLL3 is also expressed in GI
HGNEC. One study reviewed DLL3 expression in GI HGNEC
and found strong expression of DLL3 in patient tissue samples
with levels comparable to SCLC (140).
DLL3 expression is a potential therapeutic target for DLL3
targeting agent. One such agent is Rovalpituzumab-tesirine
(Rova-T) a DLL3 targeting antibody drug conjugate (139, 141,
142). Rova-T was evaluated in a phase 1 study and then a phase 2
study which confirmed antitumor activity but was notable for a
high percentage of a patients with adverse events (141, 143). A
new formulation was recently developed called SC-002 which
uses a different linker leading to a more uniform drug antibody
ratio, which was thought to improve safety. A phase I study of this
new formation was done and included 35 patients all with DLL3-
high (≥75%) expressing SCLC or LCNEC. In this study 66% of
patients experienced serious adverse events, of which 37% were
considered related to the drug. However, 14% of patients achieved
partial response (144). Further research is needed to evaluate
whether DLL3 -targeted antibody-drug conjugates can be used in
this patient population. In addition to antibody-drug conjugates,
bispecific T cell engagers and chimeric antigen receptor T cell
therapy targeting DLL3 are also in development (145).
Aurora kinase inhibitors are another potential target in SCLC
which are also promising in LCNEC. A recent study examined
subgroups of LCNEC including subtypes defined by TTF-1 and
c-Myc, which have been previously described as clinically
relevant subgroups in SCLC. They also examined DLL3 in this
patient population. IHC of lobectomy and biopsy specimens was
reviewed for 27 patients with pulmonary LCNEC. Positivity for
c-MYC was defined as cases where ≥40% tumors cells reacted
with any intensity; positivity for TTF-1 expression was defined
cases where >10% of the tumor cells reacted with any intensity.
The authors identified 10 cases with only TTF-1 and 15 cases
with only c-MYC present, 2 cases were positive for both. DLL3
was found in 15 patients and was associated with TTF-1
expression. They conclude that LCNEC, similar to SCLC can
be further divided into subgroups by TTF-1 and c-MYC
expression (146). This has important treatment implications as
c-MYC expression is associated with aurora kinase expression
and may indicate responsiveness to aurora kinase inhibitors
(147). Further studies should include biomarker correlates to
help identify subgroups of LCNEC that may best respond to
specific treatments.
Somatostatin targeting agents including somatostatin
analogues and Peptide Receptor Radionuclide Therapy (PRRT)
are effective in well-differentiated neuroendocrine tumors.
Research is ongoing as to determine the efficacy in HGNEC
including LCNEC. Case reports describe promising response to
PRRT in patients with pulmonary LCNEC with positive
somatostatin receptor scintigraphy (148). Immunohistochemical
analysis of SSTR-2 expression in pulmonary neuroendocrine
tumors was reviewed retrospectively in a series of 218 “clinically
aggressive cases” including 60 LCNEC. They found that SSTR-2 was
expressed in 33% of LCNEC and 38% of SCLC (73). Another study
reviewed immunohistochemical analysis of SSTR-2 expression of GI
HGNEC including 142 patients with LCNEC. In the LCNEC group,
22.1% of these patients had strongly positive expression of SSTR-2
(72). An analysis of somatostatin receptor scintigraphy in
pulmonary LCNEC was done in 26 patients with technetium-
99m ethylene diamine-diacetic acid/hydrazinonicotinyl-Tyr3-
octreotide (Tc-TOC). This study found that 100% of primary
lesions showed uptake of Tc-TOC while 84% of metastases were
visualized (as compared to conventional imaging) (149). Another
study retrospectively examined 26 patients with primary pulmonary
LCNEC and compared them to 40 patients with adenocarcinoma.
In this study, 50% of patients had high expression of somatostatin
receptors (150). Another retrospective study examined 18
consecutive patients with resected pulmonary LCNEC who
underwent preoperative indium In-111 pentetreotide scintigraphy.
Of this group, 10 patients (55.5%) had positive OctreoScan scans. In
this study all patients with TNM pathologic stage higher than Ib
received post-operative radiotherapy. Those with positive SRS
avidity received post-operative octreotide LAR; of these patients 9
were still alive and disease free at the time the study was published
(151). Further studies are needed to better understand the role of
SSTR-2 directed therapy in LCNEC.
CONCLUSION
LCNEC are rare and aggressive tumors, and current evidence
suggests surgery for local disease with platinum and etoposide or
platinum and irinotecan based adjuvant chemotherapy is the
most effective treatment. In advanced disease, the historical
regimen of platinum based therapy in combination with
etoposide or irinotecan remains among the commonly used
first line therapies, however for extra thoracic LCNEC regimens
like FOLFOX, FOLFOIRI and CAPTEM can also be used. Further
effective and safe treatment options are desperately needed.
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